Skip to main content

Drug Interactions between heparin and Xigris

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

heparin drotrecogin alfa

Applies to: heparin and Xigris (drotrecogin alfa)

MONITOR CLOSELY: The concurrent administration of therapeutic doses of heparin (greater than 15 units/kg/hour) and drotrecogin alfa may increase the risk of serious or life-threatening bleeding due to additive or synergistic effects on the clotting cascade. Drotrecogin alfa inactivates blood clotting Factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Most severely ill septic patients are already at a high risk of bleeding due to coagulopathies with prolonged APTT and prothrombin times (PT).

MANAGEMENT: When making the decision to administer drotrecogin alfa, the increased risk of bleeding versus the benefits of therapy should be carefully considered in seriously ill sepsis patients who are concurrently receiving therapeutic heparin (greater than 15 units/kg/hour). Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In clinical trials, prophylactic low doses of heparin did not appear to affect safety; however, the efficacy of concurrent drotrecogin alfa and heparin in treating sepsis patients has not been determined.

References

  1. (2001) "Product Information. Xigris (drotrecogin alfa)." Lilly, Eli and Company

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer